Pakistan Pharmaceuticals and Healthcare Report Q3 2009

Table of Contents

Executive Summary 5
SWOT Analysis6
Pakistan Pharmaceutical Industry SWOT 6
Pakistan Political SWOT 7
Pakistan Economic SWOT 8
Pakistan Business Environment SWOT 9
Pharmaceutical Business Environment Ratings 10
Business Environment Ranking 10
Table: Asia Pacific Pharmaceutical Business Environment Ratings For Q309 10
Limits Of Potential Returns 11
Risks To Realisation Of Returns 11
Market Summary 12
Regulatory Regime13
Intellectual Property Regime 14
Shortcomings Of The Intellectual Property Environment 14
Table: Healthcare And Pharmaceutical Companies That Are Members Of The American Business Council Of Pakistan 15
Counterfeit Drugs 16
Pricing and Reimbursement Regime 17
Recent Pricing and Reimbursement Developments 17
Industry Trends And Developments 20
Epidemiology 20
Healthcare System 22
Table: Pakistan - Key Healthcare Statistics, 2007 (' 000 people, unless otherwise stated) 23
Pharmaceutical Sector 23
Traditional Medicine 25
Research and Development 25
Retail Sector 26
International Co-operation 27
Medical Devices 29
Industry Forecast Scenario 30
Overall Market Forecast 30
Table: Pakistan - Drug Expenditure Indicators, 2003-2013 31
Key Growth Factors - Industry 32
Table: Pakistan - Health Expenditure Indicators, 2003-2013 33
Key Growth Factors - Macroeconomic 34
Table: Pakistan - Economic Activity, 2006 - 2013 35
Prescription Market Forecasts36
Table: Pakistan - Prescription Market Indicators, 2003-2013 (PKRmn unless otherwise stated) 37
OTC Market Forecast 38
Table: Pakistan - OTC Drugs Market Indicators, 2003-2013 (PKRmn unless otherwise stated) 39
Patented Product Market Forecast 40
Table: Pakistan - Patented Drugs Market Indicators, 2003-2013 40
Generic Drug Market Forecast 41
Table: Pakistan - Generic Drugs Market Indicators, 2003-2013 42
Export/Import Forecasts 43
Table: Pakistan - Pharmaceutical Trade Indicators, 2003-2013 (US$mn) 44
Other Healthcare Data Forecasts 45
Table: Pakistan - Other Healthcare Indicators, 2003-2013 (per ' 000 population, unless otherwise stated) 46
Key Risks To BMI' s Forecast Scenario 46
Competitive Landscape47
Table: Pakistan' s Pharmaceutical Market In Q406 47
Company Profiles50
Leading Multinational Manufacturers 50
GlaxoSmithKline 50
Pfizer 52
Abbott Laboratories 53
Novartis 55
Sanofi-Aventis 56
Merck & Co 57
Wyeth 58
Domestic Manufacturers 59
Hilton Pharma 59
Efroze Chemical Industries 60
Ferozsons Laboratories 61
Getz Pharma 63
Pacific Pharmaceuticals 65
Country Snapshot: Pakistan Demographic Data 67
Section 1: Population 67
Table: Demographic Indicators, 2005-2030 67
Table: Rural/Urban Breakdown, 2005-2030 68
Section 2: Education and Healthcare 68
Table: Education, 2002-2005 68
Table: Vital Statistics, 2005-2030 68
Table: Employment Indicators, 2001-2006 69
Section 3: Labour Market And Spending Power 70
Table: Consumer Expenditure, 2000-2012 (US$) 70
Table: Average Annual Manufacturing Wages, 2000-2012 70
BMI Forecast Modelling71
How We Generate Our Pharmaceutical Industry Forecasts 71
Pharmaceutical Business Environment Ratings Methodology 72
Ratings Overview 72
Table: Pharmaceutical Business Environment Indicators 73
Weighting 74
Table: Weighting Of Components 74
Sources 74